Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (Nasdaq: QSI) will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel, September 14–16, 2026. On September 15, 2026, CEO Jeff Hawkins and CFO Jeff Keyes will hold one-on-one meetings and Hawkins will join a 1:30 PM ET fireside chat, with a live and archived webcast available in the Investors section of the Quantum-Si website.
Quantum-Si (Nasdaq: QSI) reported second quarter 2026 revenue of $344 thousand, down from $591 thousand a year earlier, during its transition from the Platinum platform to the anticipated Proteus protein sequencing system. Gross profit was $172 thousand with a 50% gross margin.
Total operating expenses were $25.8 million versus $30.5 million in Q2 2025, and net loss narrowed to $23.5 million from $28.8 million. Adjusted EBITDA was negative $21.2 million, compared to negative $22.2 million in the prior-year quarter. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $169.9 million.
The company updated the anticipated commercial launch of Proteus to Q2 2027 to allow an additional integrated instrument design cycle and announced a workforce reduction of about 20%, expected to yield roughly $12 million in annualized operating expense savings and extend its cash runway into Q4 2028. Quantum-Si reiterated 2026 guidance, including approximately $1.0 million in revenue and adjusted total operating expenses of $98.0 million or less, and highlighted an estimated $4 billion annual non-human proteomics market opportunity for Proteus.
Quantum-Si (Nasdaq: QSI) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. President and CEO Jeff Hawkins and CFO Jeff Keyes will host a conference call and webcast at 4:30 PM EDT to review results and provide a business update.
Investors can access the live webcast via the Investors section of the Quantum-Si website under Events and Presentations or register to receive a dial-in number and personalized PIN. An archived webcast will be available for replay after the event.
Quantum-Si (Nasdaq: QSI) granted 134,141 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on June 20, 2027, then in 12 equal quarterly installments, subject to continued employment.
Summary not available.
Quantum-Si (Nasdaq: QSI) announced an expanded multi-city roadshow for its Proteus single-molecule protein sequencing platform. The program aims to educate the market, showcase applications, and build a customer funnel ahead of Proteus’ commercial launch.
Stops span major U.S. hubs and key European research centers.
Quantum-Si (Nasdaq: QSI) granted 427,636 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on June 20, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued employment.
Quantum-Si (Nasdaq: QSI) reported Q1 2026 results and Proteus development progress on May 7, 2026. Q1 revenue was $258,000, gross profit $74,000 and net loss $21.7M. Cash and investments totaled $190.4M, expected to fund operations into Q2 2028. Key technical milestone: automated sequencing on integrated Proteus instruments with a developmental kit detecting 17 amino acids; commercial launch targeted end of 2026.
Quantum-Si (Nasdaq: QSI) will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026. Jeff Hawkins, CEO, and Jeff Keyes, CFO, will hold one-on-one meetings; Hawkins will join a fireside chat at 4:00 PM ET.
A live and archived webcast will be available in the company Investors section under Events & Presentations, and registration is offered for the live stream.
Quantum-Si (Nasdaq: QSI) announced successful sequencing on fully integrated Proteus™ instruments using a developmental KinetIQ™ Array sequencing kit that detects 17 amino acids. The company said the run—from reaction setup to data acquisition—was fully automated without user intervention.
Quantum-Si said this advances detection capabilities from 15 to 17 amino acids since December 2025 and reiterated a goal for Proteus commercial launch by end of 2026, with early access for customers planned this summer and ongoing manufacturing scale-up efforts.